NCT01441570

The Impact of Nebivolol Versus Metoprolol on Quality of Life

The Impact of Nebivolol Versus Metoprolol on Quality of Life Measures and Cost-effectiveness in Stable Renal Transplant Recipients

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 11 (actual)
• Sponsor: Brigham and Women's Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

In an open label analysis, nebivolol has been shown to have a positive impact on quality of life in the general hypertensive population. That is, patients treated with nebivolol reported less side effects compared to those treated with metoprolol. Also, more nebivolol treated patients reached normalization of blood pressure. Although there is no data, it is believed that the impact would be similar in renal transplant recipients. The primary goal of this study is to determine if nebivolol will improve the quality of life measurements of kidney transplant recipients as compared to those treated with metoprolol succinate. This will be measured by comparing the scores of four quality of life questionnaires taken before and after 12 weeks of treatment with study drug. Other aims of this study are to determine if the use of nebivolol is cost-effective in the renal transplant recipient; determine if there is a change in urine protein excretion and renal function with the use of nebivolol; and determine the number of patients that maintain or achieve a target blood pressure of ≤ 120/80 mmHg.

Conditions

• Transplant; Failure, Kidney
• Hypertension

Interventions

Type	Name	Description
DRUG	Nebivolol	Subject will take nebivolol daily for 12 weeks.
DRUG	Metoprolol succinate	Subject will take metoprolol succinate daily for 12 weeks.

Timeline

• Start date: 2012-02-01
• Primary completion: 2013-07-01
• Completion: 2013-07-01
• First posted: 2011-09-27
• Last updated: 2017-04-20
• Results posted: 2017-04-20

Locations

2 sites across 1 country: United States